[Prognostic value of epidermal growth factor receptor].
The activation of the epidermal growth factor receptor (REGF) participates in oncogenesis by inducing cell proliferation, cell mobility and angiogenesis, and inhibiting apoptosis. This activation might be due to numerous abnormalities, including increased expression of its ligand. Although based on retrospective analyses with no standard technique of evaluation, the level of REGF expression is a prognosis factor for several tumors. It appears to be an indicator of poor prognosis which might influence treatments in head and neck tumors, cancers of the cervix, oesophagus, bladder and ovary. Its prognostic value is not observed in non-small cell lung cancer and remains to be demonstrated in adenocarcinomas such as colorectal tumors and beast cancer. Because of its role in oncogenesis and its prognostic value, REGF might in the future become a therapeutic target.
Penault-Llorca
Frédérique
F
Département de pathologie, Centre Jean-Perrin, 58, rue Montalembert, BP 392, 63011 Clermont-Ferrand. fpenault@cjp.fr
Durando
Xavier
X
Bay
Jacques-Olivier
JO
D002294:Carcinoma, Squamous Cell / Q000378:metabolism; D004815:Epidermal Growth Factor / Q000378:metabolism; D066246:ErbB Receptors / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000378:metabolism*; D009369:Neoplasms / Q000378:metabolism*; D009928:Organ Specificity; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D016211:Transforming Growth Factor alpha / Q000378:metabolism
D004815:Epidermal Growth Factor; D066246:ErbB Receptors; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D016211:Transforming Growth Factor alpha